TOPLINE: The LoDoCo2 trial found a reduced cardiovascular risk with low-dose colchicine in patients with chronic coronary disease. In this substudy, attenuation of pericoronary adipose tissue did not differ between patients receiving low-dose colchicine and those receiving placebo; however, people taking colchicine had a higher volume of dense calcified plaque…
Leave a Comment Leave a Comment
